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1INTRODUCTION
Cerebral venous thrombosis (CVT)—ie, thrombosis of the intracranial veins and
sinuses—is a rare type of cerebrovascular disease that affects about 5 people per million and
accounts for 0·5 % of all stroke. CVT was ?rst recognised at the beginning of the 19th century1
and it was long thought to be an infective disorder that commonly a?ected the superior sagittal
sinus and resulted in bilateral or alternating focal de?cits, seizures, and coma, which usually led
to death1. At that time, CVT was commonly diagnosed at autopsy and usually showed
haemorrhagic lesions, which, by analogy with arterial stroke, was thought to contraindicate the
use of heparin.
In the past 25 years, the widespread use of neuroimaging has aided early diagnosis of
CVT and has thus completely modi?ed the current information we have on this disorder. CVT
is now typically recognised as a disorder with various clinical presentations and a usually
favourable outcome, with mortality well below 10%. MRI and magnetic resonance angiography
are the best diagnostic methods for diagnosis and heparin is the ?rst-line treatment.  However,
the diagnosis of CVT is still commonly overlooked or delayed because of the remarkable
diversity of its clinical symptoms, mode of onset, and neuroimaging signs; furthermore,  a cause
cannot be found in about 15-30% of cases, the individual outcome may still be di?cult to
predict, and the disorder may occasionally worsen despite anticoagulation. CVT thus remains a
diagnostic and therapeutic challenge.
2AIM OF THE STUDY
  To study the clinical spectrum of cerebral venous thrombosis patients admitted at Government
Stanley Hospital  hospital  and to assess shortterm outcome.
3REVIEW OF LITERATURE
Cerebral veins contain about 70% of the total cerebral blood volume, but cerebral
venous sinus thrombosis (CVT) occurs less often than arterial stroke. Arterial and venous
stroke cause different neurological deficits and occur in people of different ages. About half of
the patients with an arterial stroke are older than 75 years, whereas CVT most often affects
young adults and children. It is associated with a prothrombotic state due to (inherited)
thrombophilia, other blood disorders, dehydration, infectious diseases, cancer, or more rare
causes. In about a quarter of the patients with CVT the cause remains unknown.
                 The annual incidence is currently estimated to be 3–4 cases per million people. 3 out
of 4 people with CVT are women. 1 out of 8 patients will die or remain handicapped as a result
of CVT 2  . CVT constitutes about 10-15% of young strokes. During the past decade, modern
neuroimaging techniques have improved the diagnostic process and together with the increased
awareness this will probably result in increased recognition in the future. CVT has received far
less attention in clinical research than arterial stroke. The small number of patients with CVT
limits the performance of large epidemiological studies and clinical trials on a scale comparable
to arterial stroke. .
Thrombosis of the cerebral veins may cause focal deficits due to local effects of venous
obstruction, but also more generalized effects as a result of increased cerebrospinal fluid
pressure caused by blocking of the major sinuses. In the majority of patients, these two
processes occur simultaneously. The course and clinical features of CVT are highly variable. It
is only after the introduction of computerized tomography and magnetic resonance imaging that
verification of the diagnosis during life has become part of daily clinical practice and that, as a
result, the clinical spectrum of the disease has enormously increased. It is now well known that
4the clinical features of CVT are extraordinarily variable. Consequently, the diagnosis may be
difficult. The average delay from the onset of symptoms to the diagnosis is 7 days2. Patients
may present to an ear, nose and throat surgeon with recurrent ear infections and headache, to a
pediatrician with headache and vomiting, to an obstetrician because of a complicated pregnancy
or puerperium, to an ophthalmologist because of blurred vision, to an internist because of vague
symptoms in the context of a systemic disease, to a neurologist because of epileptic seizures, or
to a neurosurgeon because of chronic intracranial hypertension.
5ANATOMY OF CEREBRAL VENOUS SYSTEM
Introduction
The veins of the brain have no muscular tissue in their thin walls and possess no valves.
They emerge from the brain and lie in the subarachnoid space. They pierce the arachnoid mater
and the meningeal layer of the dura and drain into the cranial venous sinuses.
Cerebral venous system can be divided into a superficial and a deep system. The
superficial system comprises of sagittal sinuses and cortical veins and these drain the superficial
surfaces of both cerebral hemispheres. The deep system comprises of lateral sinus, straight sinus
and sigmoid sinus along with draining deeper cortical veins. Both these systems mostly drain
themselves into internal jugular veins. The veins draining the brain do not follow the same
course as the arteries that supply it. Generally, venous blood drains to the nearest venous sinus,
except in those draining from the deepest structures, which drain to deep veins. These drain, in
turn, to the venous sinuses.
 The superficial cerebral veins can be subdivided into three groups. These are interlinked
with anastomotic veins of Trolard and Labbe. However, the superficial cerebral veins are very
variable. They drain to the nearest dural sinus. Thus the superolateral surface of the hemisphere
drains to the superior sagittal sinus while the posteroinferior aspect drains to the transverse
sinus.  The veins of the posterior fossa are variable in course and angiographic diagnosis of their
occlusion is extremely difficult.
Blood from the deep white matter of the cerebral hemisphere and from the basal ganglia
is drained by internal cerebral and basal veins, which join to form the great vein of Galen that
6drains into the straight sinus. With the exception of wide variations of basal vein, the deep
system is rather constant compared to the superficial venous system. Hence their thrombosis is
easy to recognize. Cerebral venous system can be divided into two basic  components.3,4
A)  Superficial System:
The superficial system comprises of sagittal sinuses and cortical veins and these   drain
superficial surfaces of both cerebral hemispheres.
The superficial cerebral veins can be  divided into three collecting systems5 .First, a mediodorsal
group draining into superior sagittal sinus (SSS) and the straight sinus (SS); Second, a
lateroventral group draining into the lateral sinus; and Third, an anterior group draining into the
cavernous sinus.
These veins are linked by the great anastomotic vein of Trolard, which connects the SSS
to the middle cerebral veins. These are themselves connected to the lateral sinus (LS) by the
vein of Labbe6.
The Superior Sagittal Sinus (SSS) starts at the foramen cecum and runs backwards
towards the internal occipital protuberance, where it joins with the straight sinus and lateral
sinus to form the torcular Herophili. Its anterior part is narrow or sometimes absent, replaced by
two superior cerebral veins that join behind the coronal suture.7 This fact should be borne in
mind while evaluating for cerebral venous thrombosis (CVT). The SSS drain major part of the
cerebral hemispheres.
7The cavernous sinuses drain blood from the orbits, the inferior parts of the frontal and
parietal lobe and from the superior and inferior petrosal sinuses. Blood from them flow into the
internal jugular veins.
The straight sinus is formed by the union of inferior sagittal sinus and the great vein of
Galen. The inferior sagittal sinus runs in the free edge of falx cerebri 8 and unites with the vein
of Galen to form the straight sinus. It runs backwards in the center of the tentorium cerebelli at
the attachment of the falx cerebri, emptying into the torcula Herophili at the internal occipital
protuberance.
The lateral sinuses extend from torcula Herophili to jugular bulbs and consist of a
transverse and sigmoid portion. They receive blood from the cerebellum, the brain stem and
posterior parts of the hemisphere. They are also joined by some diploic veins and small veins
from the middle ear. There are numerous LS anatomic variations that may be misinterpreted as
sinus occlusion.9
8Schematic  presentation  of cerebral  venous  system.1.Superior saggital sinus
 2.Vein of Trolard  3.Inferior saggital sinus  4.superficial middle cerebral vein
5.Vein of Labbe  6.Straight sinus 7.Torcula herophili  8.Transverse sinus
The veins of the posterior fossa may again be divided into three groups:
1) Superior group draining into the Galenic system,
2) Anterior group draining into Petrosal sinus and
3) Posterior group draining into the torcular Herophili and neighbouring transverse sinuses.6
The veins of the posterior fossa are variable in course and angiographic diagnosis of their
occlusion is extremely difficult.
9 B)  Deep System:
The deep system comprises of lateral sinus, straight sinus and sigmoid sinus along
with draining deeper cortical veins. Both these systems mostly drain themselves into internal
jugular veins.
The deep cerebral veins are more important than superficial veins from the angiographic
point of view.10 Three veins unite just behind the interventricular foramen of Monro to form the
internal cerebral vein . These include choroid vein, septal vein and thalamostriate vein. The
Choroid vein runs from the choroid plexus of the lateral ventricle. The Septal vein runs from the
region of the septum pellucidum in the anterior horn of the lateral ventricle and the
thalamostriate vein runs anteriorly in the floor of the lateral ventricle in the thalamostriate
Posterior fossa veins and their drainage system
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groove between the thalamus and lentiform nucleus. The point of union of these veins is called
the venous angle.
The internal cerebral veins of each side run posteriorly in the roof of the third ventricle
and unite beneath the splenium of the corpus callosum to form the great cerebral vein. The
internal cerebral veins, which lie within 2 mm of the midline, are the most important deep veins
since they can be used to diagnose midline shifts.11 The great cerebral vein of Galen is a short
(1-2 cm long), thick vein that passes posterosuperiorly behind the splenium of corpus callosum
in the quadrigeminal cistern. It receives the basal veins and the posterior fossa veins and drains
to the anterior end of the straight sinus where this unites with the inferior sagittal sinus. The
basal vein of Rosenthal begins at the anterior perforated substance by the union of anterior
cerebral vein, middle cerebral vein and the striate vein.12 The basal vein on each side passes
around the midbrain to join the great cerebral vein.
In summary, blood from the deep white matter of the cerebral hemisphere and from the
basal ganglia, is drained by internal cerebral veins,13 and basal veins of Rosenthal, which join to
form the great vein of Galen that drains into the straight sinus . With the exception of wide
variations of basal vein, the deep system is rather constant compared to the superficial venous
system.14  Hence their thrombosis is easy to recognize.
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Functional Anatomic Features of Cerebral Venous System
1. The cerebral veins and sinuses neither have valve nor tunica muscularis. Because they
lack valves, blood flow is possible in different directions.
2. The cortical veins are linked by numerous anastamoses, allowing the development of
a collateral circulation and probably explaining the good prognosis of some cerebral venous
thromboses.
3. Lack of tunica muscularis permits veins to remain dilated. This is important in
understanding the huge capacity to compensate even an extended occlusion. Venous sinuses are
located between two rigid layers of duramater15. This prevents their compression, when
intracranial pressure rises.
 4. Superficial cortical veins drain into SSS against the blood flow in the sinus, thus
causing turbulence in the blood stream that is further aggravated by the presence of fibrous
septa at the inferior angle of the sinus. This fact explains greater prevalence of SSS thrombosis.
5. In addition to draining most of the cerebral hemisphere, the superior sagittal sinus also
receives blood from diploic, meningeal and emissary veins. Same is the case with other dural
venous sinuses. This explains the frequent occurrence of CVT as a complication of infective
pathologies in the catchments areas e.g. cavernous sinus thrombosis in facial infections, lateral
sinus thrombosis in chronic otitis media and sagittal sinus thrombosis in scalp infections.16
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6. The dural sinuses especially the SSS contain most of the arachnoid villi and
granulations, in which absorption of CSF takes place. So dural sinus thrombosis blocks villi and
leads to intracranial hypertension and papilloedema.
7. The deep cortical veins form venous circle around the mid brain and get engorged in
superior sagittal sinus thrombosis.
INCIDENCE OF CEREBRAL VENOUS SINUS THROMBOSIS
Cerebral vein thrombosis can affect adults as well as children including neonates. The
estimated annual incidence of cerebral venous thrombosis is 3–4 cases per million in adults and
7 cases per million inchildren or neonates 17,18. Among pediatric patients, neonates are the most
commonly affected age group. Cerebral venous thrombosis is frequently reported in preschool
children. Until the mid-60s, men and women were reported to be equally affected 19. More
recently, cerebral vein thrombosis has been reported to be more common in women, particularly
in the age group between 20 to 35 years. Most Indian studies have a large number of cases
thereby suggesting that the incidence here is not as rare as previously thought of. It has been
reported to cause 10-20% of young strokes in India31. Cerebral venous thrombosis occurring in
puerperium is 10-12 times more frequent in India than Western countries.20
 The female predominance is not evident among children or elderly patients. The female
prevalence is probably due to specific age-related conditions such as pregnancy, puerperium and
oral contraceptives.CVT might complicate 11.6 per 1,00,000 deliveries.The risk of peripartum
CVT increases with hypertension, advancing   maternal age, caesarean delivery, associated
infections and excess vomiting during pregnancy.21 The rate of death from all-cause CVT is 2–
10%,   although mortality is significantly less for pregnancy-associated CVT.22
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AETIOLOGY
Several inherited and acquired predisposing factors to cerebral venous thrombosis are
recognized. However, the cause of cerebral venous thrombosis remains undefined in about one
third of the cases. In a series of patients with objectively diagnosed cerebral venous thrombosis,
no underlying cause could be identified in 20–35% of patients, even after extensive
investigation 22-24. An initial distinction should be made between infective and noninfective
causes.
 Among the infective causes, infections of the orbit, mastoid, middle ear or face and
meningitides are the conditions most commonly associated with cerebral venous thrombosis.
Infections of the mastoid or face, in particular, are predisposing factors for a venous thrombosis
in the lateral sinuses (transverse or sigmoid). Staphylococcus aureus, Gram-negative bacilli and
fungi, such aspergillus, are the most commonly isolated microorganisms in patients with otitis
and mastoiditis. Thrombosis of the cavernous sinus is nearly always caused by the infection of
paranasal sinuses (ethmoid and sphenoid) or of the orbits. Infective causes probably occur less
commonly with modern aggressive antibiotic treatment and nowadays account for no more than
10% of cases 23.
CAUSES OF CEREBRAL VENOUS SINUS THROMBOSIS
1.LOCAL
a.Head injury
b.Neurosurgery
c.Meningitides
d.Arteriovenous malformation
e.Sepsis (sinusitis, mastoiditis, cellulitis)
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f.Space-occupying lesions
g.Jugular catheterization
2.SYSTEMIC
a.Dehydration (diabetic ketoacidosis)
b.Septicemia
c.Pregnancy and puerperium
d.Inflammatory bowel disease
e.Malignancy
f.Sarcoidosis
g.Collagen disease (Behcet’s syndrome, SLE, Sjögren’s syndrome)
h.Hyperhomocysteinemia
i.Nephrotic syndrome
j.Autoimmune thyroiditis
3.DRUGS
a.Oral contraceptives
b.Hormone replacement therapy
c.Androgens
d.L-asparaginase
e.Ecstasy
4.BLOOD DYSCRASIAS
a.Leukemia
b.Myeloproliferative disorders
c.Thrombocythemia
d.Sickle-cell trait
e.Paroxysmal nocturnal hemoglobinuria
f.Thrombotic thrombocytopenic purpura
g.Heparin-induced thrombocytopenia
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5.COAGULOPATHIES
a.Protein S, protein C, antithrombin III deficiency
b.Factor V Leiden mutation
c. Antiphospholipid antibodies.
Among the non-infective causes of cerebral venous thrombosis, the most common are
cancer, myeloproliferative disorders, dehydration, oral contraceptives, disorders of blood
coagulation, collagen diseases and pregnancy or puerperium.
The mechanical causes such as head trauma, neurosurgical procedures or jugular
catheterization are considered to be conditions potentially predisposing to cerebral venous
thrombosis. A lumbar puncture can also lead to thrombotic complication of the cerebral veins.
A plausible explanation seems to be the reduction in the cerebrospinal fluid pressure due to the
procedure where it can generate a dislocation of the brain with traction of its venous structures.
Cerebral venous thrombosis can occur in patients with both inherited and acquired
thrombophilic states. Among the inherited conditions, factor V Leiden and prothrombin gene
mutations, deficiencies of protein C, S and antithrombin are the most common. It is estimated
that these deficiencies account for 10–15% of cases 8,  9. It has been reported that
hyperhomocysteinemia is associated with a 4-fold increased risk of cerebral vein thrombosis27.
Among the acquired conditions, the antiphospholipid antibody syndrome is associated with an
increased risk of cerebral venous thrombosis 25.
The use of oral contraceptives and, less frequently, hormone replacement therapy has
been associated with the increased risk of venous thrombosis, including cerebral venous
thrombosis. A recent crossover study reported increase in the level of factor VII, factor VIII,
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factor X, fibrinogen and pro-thrombin fragment 1 + 2 and decrease in the level of factor V
during the use of oral contraceptives. These findings were more pronounced in women on third-
generation oral contraceptives (containing desogestrel or gestodene).
The association of acquired predisposing conditions with genetic abnormalities increases
the risk of developing cerebral venous thrombosis. The use of oral contraceptives in carriers of
thrombophilic abnormalities appears to be associated with increased risk of cerebral venous
thrombosis 27.  De  Bruijn  et  al. 27 reported a 30-fold increased risk for cerebral venous
thrombosis in women with a combination of thrombophilic abnormalities and use of oral
contraceptives, as compared to women without either risk factor27. A case report described
cerebral venous thrombosis associated with the use of androgens in an otherwise healthy young
man 13
During pregnancy or puerperium, a significant increase in the risk of cerebral venous
thrombosis was associated with caesarian delivery, increasing maternal age, presence of
comorbidities including hyperemesis, intercurrent infections and maternal hypertension.  A
cumulative effect of resistance to activated protein C during pregnancy and decreased protein C
levels following caesarian delivery has been recently postulated 28,29
Obstetric CVT is much more common in the puerperial period than in pregnancy,
particularly in the first 3 weeks after delivery, with 15% of cases occurring in the first 2 days .
When CVT is seen in pregnancy, it can occur in any trimester. It has been suggested that
pregnancy/puerperium-related CVT may more commonly have a sudden or acute onset, and a
progressive course that tends to become stable in a few days and a better prognosis than
nonobstetric CVT . Many risk factors have been implicated in the pathogenesis of peripartum
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and puerperial CVT. These include dehydration, anemia, cesarean delivery, hypertension,
infections, the mother’s age (more common in women aged 15–24 years than in those aged 25–
34 years), and thrombophilia . Some studies imply that anesthesia (dural puncture) performed
for cesarean delivery may be responsible for some cases .
Physiological changes predisposing to CVST in pregnancy and puerperium
a.Increased Von-Willebrand factor
b.Increased factor I,VII,VIII,X
c.Increased fibrinogen
d.Protein C resistance & reduced protein S concentration
e.Incresed plasminogen activator inhibitors 1 and 2
f.Anaemia of pregnancy
g.Fluid restriction leading to dehydration and changes in blood flow
Cerebral vein thrombosis, although uncommonly, may be a manifestation of collagen
disorders (such as systemic lupus erythematosus, Behcet’s disease, Sjögren’s syndrome) or
inflammatory bowel disease.
Cerebral venous thrombosis can be a complication of nephrotic syndrome and allogeneic
bone marrow transplantation. In the case of nephrotic syndrome, renal loss of antithrombin III
has been postulated as the potential mechanism for cerebral venous thrombosis. Several
hematological disorders have been linked to CVT; these are polycythemia, paroxysmal
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nocturnal hemoglobinuria sickle cell disease , idiopathic hypereosinophilic syndrome,
hemolytic anemia , and thrombocythemia .
In a case-control study30, severe anemia was significantly more frequent in CVT patients
.Severe anemia was associated with thrombocytosis (81%) and was microcytic in (63%). There
are three proposed hypotheses why iron deficiency anemia causes thrombosis/ischemia.
1. thrombocytosis occurs secondary to iron deficiency anemia and may be associated
with a hypercoagulable state;
2. iron deficiency is thought to contribute to a hypercoagulable state by altering flow
patterns in vessels because of reduced red cell deformity and increased viscosity;
3. hypoxia secondary to iron deficiency anemia can occur in situations of increased
metabolic stress, such as dehydration and infection.
PATHOGENESIS
              Two different mechanisms have been identified; however, they are interrelated in many
cases. The occlusion of a cerebral vein leads to localized brain edema and a so-called venous
infarction. During pathological examination, swollen veins, edema, ischemic neuronal damage
and petechial hemorrhages that can merge and become a large hemorrhage are observed.
Cytotoxic edema caused by local ischemia, subsequently damages the energy-dependent cellular
membrane pumps and induce intracellular swelling. Vasogenic edema caused by disruption in
the  blood-brain  barrier  and  leakage  of  plasma  into  the  interstitial  space  is  a  reversible
phenomenon. The occlusion of a major sinus leads to the development of intracranial
19
hypertension because of an impaired absorption of cerebrospinal fluid. The ventricles do not
dilate and no hydrocephalus occurs because there is no gradient of pressure
CLINICAL PRESENTATION OF CEREBRAL VENOUS SINUS
THROMBOSIS
Cerebral venous pathology is significantly less common than arterial pathologies.
Symptoms are often nonspecific and are related to the specifically involved venous structure, to
the presence of valid collateral system and to intracranial hypertension. Unlike in arterial stroke,
the symptom onset in cerebral venous thrombosis is usually subacute (2 days to 1 month; 50–
80%), in some cases it can be acute (2 days or less) and simulate arterial stroke (20–30%). In
patients presenting with isolated intracranial hypertension, the onset of symptoms can be
chronic (more than 2 months; 10–20%) 32. Occasionally, symptoms can progress over more than
6 months33.
 Signs and symptoms (%) in patients with cerebral venous thrombosis 35
Headache  92%
Papilledema  45%
Motor deficit  42%
Seizures 37 %
Encephalopathy 31%
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Isolated intracranial hypertension 29%
Delirium 25%
Aphasia 18%
Stupor/Coma 13%
Sensorial deficit 11%
Oculomotor nerve palsy 10%
Visual deficit 9%
Meningeal signs 5%
Hemianopia 4%
Cerebellar signs 4%
Cerebral venous thrombosis has a more progressive development, strong tendency to
fluctuate, association with other manifestations of increased intracranial hypertension and
seizures. Other differences are: venous cerebral infarct usually does not fit into an arterial
territory, more often it is bilateral and hemorrhagic transformation of the lesion is quite
frequent.
The most common symptoms and signs are headache and papilledema due to
intracranial hypertension, seizures, focal neurological deficits, and altered consciousness. These
can be present alone (pure headache, pure seizures, pure intracranial hypertension) or in
association. With decreasing frequency, patients present with one of the following clinical
21
syndromes34: isolated intracranial hypertension with headache and papilledema; headache plus
focal neurological deficits and focal seizures; isolated cranial nerve lesions with headache;
subacute unspecific encephalopathy; sinus cavernous syndrome with chemosis, protrusion  of
bulbi and painful ophthalmoplegia;.
1.HEADACHE
It is the most common symptom and it is present in up to 80 -90% of all patients.
Headache can present as migraine in migraine patients or tension type headache, but it is usually
progressive, continuous and refractory to medical treatment. The mechanism of the headache
remains unknown in most cases. The two plausible hypotheses are stretching of nerve fibres in
the walls of the occluded sinuses and local inflammation.
Most patients who are admitted for other neurological symptoms often complain of headache at
admission or report a history of headache of unusual type that started a few days or weeks
earlier.
Headache may occur in a context of isolated intracranial hypertension: patients with a
chronic course or with delayed clinical presentation may have papilloedema
Headache may also be the only symptom and occurs in the absence of intracranial hypertension,
subarachnoid hemorrhage or meningitis 36,37. Isolated headache is sometimes of the thunderclap
type, mimicking a subarachnoid hemorrhage.
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Headache attributed to CVT: Diagnostic criteria of International
classification of Headache Disorders. 23
A.Any new headache, with or without neurological signs,fulfilling criteria C and D
B.Neuroimaging evidence of CVT
C.Headache (and neurological signs if present) in close  temporal relation to CVT
D.Headache resolves within 1 month after appropriate treatment.
2.VISUAL DISTURBANCES
Patients affected by cerebral venous thrombosis can present with threatened vision,
visual obscuration, visual loss and constriction of the visual field. 38. These symptoms can be
related to either the presence of cerebral infarct (involving optic radiations or occipital cortex)
or to papilledema, due to intracranial hypertension. Papilledema on fundoscopy can be initially
evidenced as optic disc swelling, elevating and blurring. Over a few days, retinal exudates,
splinter hemorrhages and infarcts can be observed. Papilledema frequency ranges from 45 to
86% in all cerebral venous thrombosis cases  but this finding is less common in acute cases.
Furthermore, papilledema is commonly associated with other signs of intracranial hypertension
such as headache, vomiting and bradycardia. In the absence of treatment, papilledema is known
to lead to optic atrophy 39.
3. ISOLATED INTRACRANIAL HYPERTENSION
Cerebral venous thrombosis can be overlooked when intracranial hypertension is
isolated. In a series of patients affected by cerebral venous thrombosis, 37% had intracranial
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hypertension as the only sign of cerebral venous thrombosis. Cerebral venous thrombosis can be
present with all the classical criteria for idiopathic intracranial hypertension, including normal
brain computed tomography (CT) with normal cerebrospinal fluid (CSF) content. Then
magnetic resonance imaging (MRI), with magnetic resonance venography should be performed,
when necessary, also in patients with isolate intracranial hypertension.
4. FOCAL CEREBRAL SYMPTOMS
Seizure frequency has been reported to range from 10 to 60% in published series.
Seizures occur more frequently in children (58%) and neonates (71%)40. Early symptomatic
seizures were found in 44.3% of all patients while status epilepticus was found to occur in
12.8% of patients 41. Motor deficit, intracranial hemorrhage, and cortical vein thrombosis are
independent predictors of early epileptic seizures. Seizures are about equally divided between
focal and generalized types; the association of both  types is very common. Seizures are usually
generalized in patients with isolated intracranial hypertension; by contrast, they are common
and often partial in patients who have focal deficit. The antiepileptic treatment should be started
when the seizures are part of the clinical picture. Prolonged treatment with antiepileptic drugs
for 1 year could be reasonable for patients with early seizures and hemorrhagic lesions on CT
scan 42.
Focal neurological deficits such as paresis, dysphasia, visual-spatial disorders, and
homonymous hemianopia are inaugural symptoms in 15% of patients affected by cerebral
venous thrombosis and they can be observed in up to 50% during the course of the disease.
Focal neurological signs are associated with the presence of large cerebral infarct with or
without hemorrhagic transformation: Bilateral cerebral infarcts with bilateral symptomatology
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are common and among their focal symptoms the most common is hemiparesis or hemiplegia
present in 34–43% 32. Motor deficits are known to worsen over days and predominantly affect
the  legs.  Patients  with  motor  or  sensory  deficits,  associated  with  parenchymal  lesions
accompanied by an involvement of sagittal sinus and cortical vein thrombosis tend to have more
epileptic seizures 43. In rare cases, focal neurological deficits are transient and mimic transient
ischemic attack 44.
Disturbance of consciousness as the initial sign of cerebral venous thrombosis is rare,
although it can be present when the thrombosis affects the deep venous system. Patients may be
comatose when a large unilateral infarcts or hemorrhages compress the diencephalons and
brainstem, when thrombosis involves the deep grey matter of the thalamus and corpus striatum,
hypothalamus, ventral corpus callosum, medial occipital lobe and the upper part of the
cerebellum.
Cranial nerve palsies are reported in 12% of all cases of cerebral venous thrombosis.
The cranial nerves that have been described to be involved are III, IV, V, VI, VII, VIII, IX, X
and XI, and the involvement can be multiple or single.
An isolated peripheral facial nerve palsy was described for segmental occlusion of the
ipsilateral transverse sinus 45 . In the case of thrombosis of the petrosal sinuses, it is mainly
characterized by a V nerve palsy for the superior sinus and a VI nerve palsy for the inferior one
46, 47 .In patients with lateral sinus thrombosis, diplopia due to VI nerve palsy and signs of V
nerve irritation with temporal and retro-orbital pain,occurs and it has been known as the
Gradenigo syndrome, suggesting involvement of the nerves at the petrous apex. The unilateral
or bilateral VI cranial nerve involvement can also be due to the intracranial hypertension itself.
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The involvement of the III, IV, V and VI cranial nerves can be due to the thrombosis of the
anterior cavernous sinus. An involvement of the IX, X and XI cranial nerves is possible when
there is  thrombosis is the posterior cavernous sinus or the internal jugular vein, or the deep
venous  system  or  the  cerebellar  veins.  In  this  latter  case,  other  symptoms  due  to  the
involvement of the brainstem, such as limb or gait ataxia and impaired consciousness, may be
present.
5.NEUROPSYCHOLOGICAL DEFICITS
Impaired anterograde memory, dementia, akinetic mutism, and abnormal movements
such as athetoid movements and dystonia, can in rare cases be symptoms of deep cerebral
venous thrombosis.
6.SUBACUTE DIFFUSE ENCEPHALOPATHY
A generalized encephalopatic illness without localizing signs or recognizable features of
raised intracranial pressure is another pattern of presentation 48.  A  depressed  level  of
consciousness is the most constant finding, varying from  drowsiness to deep coma. This type of
presentation is extremely misleading
7.UNUSUAL PRESENTATION OF CVT
a..Subarachnoid hemorrhage has been described as the initial presentation of dural sinus
thrombosis 49 .Patients with cerebral venous thrombosis can present with headache of sudden
onset, neck stiffness and imaging evidence of subarachnoid hemorrhage simulating a ruptured
intracranial aneurysm.
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b..Isolated psychiatric symptoms such as irritability, anxiety, depression, psychosis,
delirium and amnesia are known to be the prevailing symptoms of cerebral venous thrombosis.
They can be misleading in the postpartum period.
c..Reversible parkinsonism and MRI diffusion abnormalities 50 have been  described as a
presenting symptom of cortical venous thrombosis.
d..Specific occasional manifestations such as trigeminal neuralgia have been reported in
cerebral venous thrombosis. In this case report51 trigeminal-like neuralgia was associated with
intracranial hypertension secondary to thrombosis of the deep cerebral venous system.
e..Acute visual loss , acute micrographia and hypophonia , migraine like phenomena,
hearing loss , ocular flutter (intermittent bursts of conjugate horizontal saccades without
intersaccadic interval)  and dizziness when eating  have been described as the only symptoms of
cerebral venous thrombosis.52-57
f..Finally, cerebral venous thrombosis can also be asymptomatic, particularly in the case
of lateral sinus thrombosis, which can be observed on a routine CT scan 58.
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TOPOGRAPHIC PATTERN
The location of the thrombosis can determine characteristic clinical  patterns.
1.The superior sagittal sinus thrombosis is present in from 72 to 92% 22,23 of  all  of
cerebral venous thrombosis cases. Patients can present with typical symptoms of isolated
intracranial hypertension with headache, foggy vision, visual loss, nausea, vomiting and cranial
nerve palsy Yet, more frequently, thrombosis of the superior sagittal sinus can lead to
deficiency syndromes with cortical signs such as aphasia, hemianopia and neglect. At the same
time, superior sagittal sinus thrombosis can produce cranial nerve palsy, hypoesthesia and
hemiparesis that normally worsen over time.
2.Lateral sinus  is involved in about 10% of the cases. When isolated, it is known to be
asymptomatic and headache can be the exclusive symptom. When this type of thrombosis
extends to the contiguum sinuses (superior sagittal sinus, deep venous system, superior and
inferior sinuses),intracranial hypertension, depressed consciousness, focal cerebral signs and
cranial nerve palsies (IX-X-XI) 23 may be present.
3. When thrombosis extends to the cerebellar vein, patients with isolated headache
develop vomiting and limb or gait ataxia. Involvement of cranial nerves (IX, X) can indicate the
involvement of the internal jugular vein.  Cortical vein thrombosis is rare (2–5%), usually
asymptomatic.
4. Cortical vein thrombosis becomes symptomatic when associated with the presence of
parenchymal lesions, which usually consist of large cortical infarcts associated with an acute
motor deficit predominantly affecting a leg, cortical signs and epileptic seizures.
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5. Occlusion of the deep cerebral veins is the clinically most obscure of the venous
syndromes. Thrombosis of the deep venous system should be strongly suspected in patients
presenting with headache, nausea, vomiting, nystagmus, paresis, limb or gait ataxia and
impaired consciousness. Isolated depression and disorientation due to bilateral thalamic lesions
has been described 59. Thrombosis of the deep venous system has a poor outcome;
neuropsychological deficits such as impaired anterograde memory, dementia, hemiparesis,
akinetic mutism, and abnormal movements as athetoid movements and dystonia represent
frequent sequelae 60.
6.Cavernous sinus thrombosis is rare and represents about 0.5–2% of all cerebral venous
thrombosis ; it can have infective etiology especially in younger patients  Onset in the anterior
cavernous sinus thrombosis is abrupt with headache, ocular pain, chemosis, proptosis, ocular
nerve palsy (III, IV, VI and the ophthalmic division of V) and fever in the case of infective
etiology.
7.Internal jugular vein can be affected by cerebral venous thrombosis. In most cases, the
thrombosis extends from the sigmoid sinus. Swelling and pain in the mastoid region, and a
palpable, tender thrombosed vein can be observed. Jugular vein thrombosis is most commonly
asymptomatic when isolated.
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CVT  IN ELDERLY
In ISCVT, 8.2% of patients were aged 65 years or over. When cerebral venous
thrombosis affects elderly patients 61  ,isolated intracranial hypertension syndrome and severe
headache are less common, whereas depressed consciousness and mental status changes are
more frequent. The prognosis for elderly patients is usually considerably worse. There were no
differences between the two groups in the site and number of occluded sinuses and the presence
and type of parenchymal lesions.
DIAGNOSIS OF CVT
 COMPUTATED AXIAL TOMOGRAPHY
Plain, noncontrast, CT of the brain shows nonspecific  subtle abnormalities in most
patients with CVT. CT may be interpreted as ‘normal’ in 25–40% of patients, later proven to
have CVT. The main utility of plain CT in patients with suspected CVT is to rule out other
pathologies, such as tumors. Contrast administration is always required to increase the
reliability of CT in diagnosing CVT. However, CT, plain or with contrast, cannot unequivocally
confirm the diagnosis of CVT in a large number of patients 62,63. Additional imaging modalities,
such as MRI/MRV, are often needed. The following findings on CT should raise suspicion for
CVT in patients whose clinical findings suggest the diagnosis.
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INDIRECT SIGNS
1. Erosion of middle ear structures and changes in the mastoid region .These changes are
especially seen in patients with septic lateral sinus thrombosis.
2. Hydrocephalus and compression of the fourth ventricle. These changes may be seen in
patients with cerebellar sinus thrombosis and venous infarcts.
3. Parenchymal changes include venous infarct localized or diffuse brain edema and sulcal
effacement and enhancement of the falx and tentorium. Venous infarcts can be hemorrhagic or
nonhemorrhagic. They are present in up to 40% of patients with CVST, the majority of which
are hemorrhagic 62,63
The following red flags should raise suspicion for venous infarcts: (1) multiplicity; (2) non-
arterial territory; (3) subcortical localization; (4) ill-defined appearance, and (5) bilateral
involvement of the thalami or basal ganglia 17, 62.. Hypodensity around hypertensive and non-
CVT related hemorrhages due to oedema develops gradually during a 24- to 72-hour period and
is usually symmetrical surrounding the hematoma.
4. The ventricles are sometimes small and slit-like as a result of increased intracranial pressure
and associated edema. Occasionally, isolated gyral or linear enhancement is seen, and may be
misinterpreted as ‘subarachnoid hemorrhages’.
DIRECT SIGNS
1. The cord/dense sign. In 2–25% of patients, the fresh thrombus can be visualized as a subtle
focus of hyperdensity within the occluded sinus on plain CT This is best seen within the large
straight and superior sagittal sinuses62.
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2.The dense delta (filled triangle) sign.  This  is  seen  on  plain  CT,  as  a  dense  triangle  (from
hyperdense thrombus) within the superior sagittal sinus. It is seen in up to 60% of patients.
However, this is not specific 62.
3.The empty delta (empty triangle) sign. This is seen on CT after contrast administration, as a
bright triangle surrounding a central hypodense core. It represents contrast enhancement of the
dilated collaterals surrounding the clot. It is seen in 25–52% of patients with sagittal, straight,
and lateral sinus thrombosis 64. This sign must be carefully interpreted, since false negatives and
false positives are not uncommon. The presence of both the empty and dense delta signs
increases the likelihood of the diagnosis of CVT.
MAGNETIC RESONANCE IMAGING
MRI has become the imaging modality of choice for the diagnosis of suspected CVT. Its
multiplanar imaging capabilities and lack of bone artifacts make it more sensitive than CT to
detect parenchymal abnormalities, petechial hemorrhages, thrombus formation, and blood flow.
MRI, therefore, is superior to CT in providing definitive evidence for CVT.  MRI findngs
depend on the sequence used and stage (age) of the thrombosis.
STANDARD SPIN ECHO T1- AND T2-WEIGHTED MRI
The main direct sign of CVT on a standard MRI protocol is the lack of expected signal
flow void on standard spin echo T1W and T2W sequences 65, 66..Alterations in blood flow and
hemoglobin degradation products in thrombosed veins produce signal changes on MR T1- and
T2-weighted images, which suggest CVT . Any of the following MRI findings can be seen.
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 At a very early acute stage (day 1–5), there is an absence of flow void and the thrombi
appear isointense on T1W and hypointense on T2Wweighted images due to the presence of
oxyhemoglobin in the intact red blood cells. A hypointense signal using T2W was detected in
90% of sites of venous thrombosis at the ?rst MRI investigation.The better sensitivity of T2W
was clearly significant within the ?rst 3 days of symptom onset, with respective frequencies of
hyposignal on T2W in over 90% and. T2W is particularly useful in isolated cortical venous
thrombosis and during the very early days of acute CVT .
At the subacute stage (day 6–21), the thrombus becomes hyperintense, initially on T1-
(day 6–9) then on T2-weighted images (day 10–15), due to the conversion of oxyhemoglobin to
methemoglobin. Absence of flow void persists. In large sinuses, hyperintensity of the thrombus
proceeds from the periphery inwards. This can be seen as a hypointense thrombus surrounded
by a circumferential hyperintense rim, ‘the target sign’. Increased signal intensity on both T1
and T2 images is the most frequent MRI finding in patients with CVT.
At the chronic stage (21–35 days), the MRI pattern is more variable. The thrombosed
sinus can either remain totally or partially occluded or can recanalize. In most patients, the
chronic thrombus appears heterogenous, becoming progressively isointense on T1 images and
isointense to hyperintense on T2 images.
MAGNETIC RESONANCE VENOGRAPHY
MRV has become the imaging modality most widely used to establish the diagnosis of
CVT. MRV can be performed with time of flight (TOF) or phase contrast techniques (PCT)65
TOF relies mainly on flow-related enhancement for producing vascular images, whereas PCT
uses velocity-induced phase shifts to distinguish moving blood flow from the surrounding
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stationary tissue. Absence of flow signal within a sinus and its non opacification suggest
intraluminal thrombosis .The occluding thrombus often appears hyperintense.
CEREBRAL CT VENOGRAPHY
Recently, dynamic spiral CT techniques have been utilized to study the cerebral venous
circulation. Spiral cerebral CT venography can be easily and rapidly performed in the acute
setting, immediately following noncontrast CT.Filling defects within the affected sinuses, sinus
wall enhancement and abnormal venous collaterals are the usual findings . This modality can be
particularly useful in hospitals where timely access and availability of MRI or conventional
angiography is limited. CTV images are not impaired by in-plane flow signal loss seen with
MRV, and may be superior to MRV in visualizing sinuses or smaller veins with low flow 67.
Conventional Angiography
A four-vessel cerebral angiogram allows visualization of the entire venous phase.
However, its utility in recent years has declined because of its invasive nature and increased
availability of MRI/MRV and CT/CTV techniques. Failure of a sinus/vein to fill (opacify)
throughout all or most of its course suggests thrombosis. Dilated, tortuous venous collaterals
extending away from the occluded sinus or vein, and a prolonged contrast blush in the brain
parenchyma further support the diagnosis . An empty delta sign may also be seen on frontal
views in cases of superior sagittal sinus thrombosis. The use of cerebral angiography to
diagnose CVT has limitations.
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Transcranial Doppler
Ultrasound techniques may have a role in diagnosing CVT 68 Thrombosis of the superior
sagittal sinus or deep basal veins of Galen, Labbé or Rosenthal can be associated with increased
flow velocities in the deep venous system. It has been suggested that serial transcranial Doppler
(TCD) evaluations may be useful in monitoring changes in venous flow and response to
treatment. However, available data about the utility of  TCD in CVT are limited, and the
reliability of TCD findings needs confirmation.
D-Dimer
                Due to the wide range of symptoms that are compatible with a diagnosis of CVST, it would
have been useful to have a test that is noninvasive, cheap, easy to perform in emergency and that would
confidently rule out CVT in patients with nonspecific symptoms such as isolated headache. Several
studies have tested the value of D-dimer measurements, because in patients with deep vein thrombosis of
the legs, a value below  500  ng/mL has a high negative predictive value. In fact, in most patients with
recent CVT, there is an increase in D-dimer concentrations; this implies that a low value of D-dimer
makes the diagnosis of CVT unlikely. However, the negative predictive value of low D-dimer
concentrations is good in patients with encephalic signs, who anyway should undergo MRI, but not in
those with isolated headache.  Thus, a negative D-dimer assay cannot rule out CVT in patients with
recent isolated headache  and cannot be recommended as a screening test69,70
35
TREATMENT OF CEREBRAL VENOUS THROMBOSIS
Recent guidelines have been published for the treatment of CVT, which combines causal
treatment to speci?cally manage the various causes, antithrombotic treatment, and symptomatic
treatment—ie, treatment of intracranial hypertension, seizures, headache, and visual failure. The
aims of antithrombotic treatment in CVT are to recanalise the occluded sinus or vein, to prevent
the  propagation of the thrombus, and to treat the underlying prothrombotic state—in order to
prevent venous thrombosis in other parts of the body, such as pulmonary embolism—and to
prevent the recurrence of CVT.
 HEPARIN THERAPY
Heparin as a treatment for CVT was advocated by Martin and Sheehan 60 years ago and
is  still considered to be the standard therapy.  Antithrombotic agents may limit the spread of
thrombus and promote its dissolution. Low molecular weight heparin or heparinoids when
compared with unfractionated heparin have a longer half life, predictable response to ?xed
dosing, and a lower incidence of thrombocytopenia and haemorrhagic complications.
Intravenous heparin should be the ?rst-line treatment for CVT, even in the presence of
haemorrhagic infarction, provided there are no general contraindications to its use. If the patient
deteriorates despite adequate heparinisation or presents moribund with coma, selective catheter-
guided local thrombolysis may be an option, in spite of the increased haemorrhagic risk. This
should be followed by 3–6 months of oral anticoagulation.
Dose-adjusted intravenous heparin treatment should be started immediately with a bolus
of 3,000–5,000 IU after the diagnosis, even if a hemorrhagic infarct is present. The aPTT should
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at least be doubled. Continuous treatment using an intravenous infusion system is started with
1,000–1,200 IU per hour, followed by an increase of 100–200 IU per hour every 6–8 h until
aPTT is doubled. The required heparin dosage varies significantly among patients but
administration of very high dosages (2,000–3,000 IU/h) may reflect antithrombin III deficiency
or. Alternatively, LMWH (e.g. nadroparin in a dose of 180 antifactor Xa U/kg/24 h
administered by two subcutaneous injections daily) can be given particularly in uncomplicated
cases. A meta-analysis which compared the efficacy of fixed dose subcutaneous LMWH versus
adjusted dose unfractionated heparin for extracerebral venous thromboembolism found a
superiority for LMWH and significantly less major bleeding complications 71. .Further
advantages of LMWH include the route of administration which increases the mobility of
patients and the lack of laboratory monitoring and subsequent dose adjustments. Heparin
therapy should be continued until remission of the acute stage of the disease (normalizing level
of consciousness or remission of mental confusion, improvement of headache and focal
neurological deficits).
ORAL ANTICOAGULANTS
After the acute stage, therapy is switched over to oral AC. Three tablets (3mg per tablet)
are given as a single dose on the 1st day of phenprocoumon therapy, followed by 2 tablets on
the 2nd and 3rd day. Further dosage is depending on the actual international normalized ratio
(INR) value with a target INR of 2.0–3.0. Effective AC must be ensured during adjustment to
coumarin or warfarin therapy. This is accomplished by continuing full-dose heparin therapy
until the INR value is in its target range. If deterioration of the clinical status appears, heparin
therapy should be resumed without termination of oral AC, because deterioration is usually due
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to ineffective AC during coumarin or warfarin adjustment. However, oral AC should be stopped
if clinical deterioration continues.
If CVT occurs during pregnancy, oral AC should be avoided due to its possible
teratogenic effect and ability to pass the placenta. In these cases, AC should be continued with
heparin. However, placenta hemorrhage with subsequent placenta insufficiency may also appear
during heparin therapy. Recanalization occurs within the first 4 months after CVT irrespective
of further AC.
Oral AC with a target INR of 2.0–3.0 may be given for 3 months if CVT was secondary
to a transient (reversible) risk factor and for 6–12 months if it was idiopathic 72. However, the
risk of recurrence of CVT may be lower than that of extracerebral venous thrombosis. In the
ISCVT, 2.2% of all patients had a recurrent sinus thrombosis with a median follow-up of 16
months 72 and prolonged AC may expose some patients to an unnecessary bleeding risk,
although there was also a risk of 4.3% for other thrombotic events during follow-up including
2.5% of pelvic or limb venous thrombosis and 0.5% of pulmonary embolism.
Oral AC is also recommended for 6–12 months in patients with extracerebral venous
thrombosis and a ‘mild’ hereditary thrombophilia such as protein C and S deficiency,
heterozygous factor V Leiden or prothrombin G20210A mutations. Long-term treatment should
be considered for patients with a ‘severe’hereditary thrombophilia which carries a high risk of
recurrence, such as antithrombin deficiency, homozygous factor V Leiden mutation, or two or
more thrombophilic conditions. Indefinite AC is also recommended in patients with two or
more episodes of idiopathic objectively documented extracerebral venous thrombosis 73. Thus,
in the absence of controlled data the decision on the duration of anticoagulant therapy must be
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based on individual hereditary and precipitating factors as well as on the potential bleeding risks
of long-term AC. Regular follow-up visits should be performed after termination of AC and
patients should be informed about early signs (headache) indicating a possible relapse.
SYMPTOMATIC THERAPY
Symptomatic therapy includes the use of antiepileptic drugs (AED), management of
increased intracranial pressure (ICP), the control of psychomotor agitation and psychotic
features if present, analgesic treatment  and the use of antibiotics in patients with septic CVT.
TREATMENT OF SEIZURES
Focal sensory and motor deficits, the presence of parenchymal lesions and intracranial
hemorrhage on admission CT/MRI and cortical vein thrombosis are independent predictors of
early symptomatic seizures 74. Although data are insufficient to give recommendations, these
findings suggest that prophylactic treatment with AED may be a therapeutic option for those
patients, whereas it is not warranted when there are no focal neurological deficits and no focal
parenchymal lesions on brain scan (e.g. patients with isolated intracranial hypertension).
The risk of residual epilepsy after CVT is low compared to the high rate of patients with
early seizures. Reported incidences range from 5 to 10.6% 75. Late seizures were more common
in patients with early symptomatic seizures than in those patients with none. Thus, prolonged
treatment  with  AED  for  1  year  may  be  reasonable  for  patients  with  early  seizures  and
hemorrhagic lesions on admission brain scan, whereas in patients without these risk factors
AED therapy may be tapered off gradually after the acute stage.
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TREATMENT OF RAISED ICP
Antiedematous treatment is necessary in only 20% of patients and should be carried out
according to general principles of therapy of raised ICP (head elevation at about 30,
hyperventilation with a target PaCO2 30–35mm Hg, intravenous application of osmotic
diuretics).
In patients with isolated intracranial hypertension and threatened vision, a lumbar
puncture with sufficient CSF removal to obtain a normal closing pressure should be performed
before starting anticoagulants 24 h after the puncture. Acetazolamide may be considered in
patients with persistent papilloedema. In few patients, vision continues to deteriorate despite
repeated lumbar punctures and/or acetazolamide. In these cases, shunting procedures
(lumboperitoneal, ventriculoperitoneal shunts or optic nerve fenestration) should be considered
73. The use of tris-hydroxy-methyliminomethane which decreases ICP after intravenous
administration via an alkalotic vasoconstriction may be a therapy option in ventilated patients.
Steroids are not generally recommended for treatment of elevated ICP since their
efficacy is unproven and they may be harmful through their promotion of the thrombotic
process. No benefit of steroids was found in a case-control study of the ISCVT 72.
In severe cases with threatening transtentorial brain herniation due to a unilateral large
hemorrhagic infarct, decompressive surgery may be the only way to save the patient’s life.
Local thrombolysis seems to be no treatment option in such cases because of the incalculable
risk of further ICH extension with an additional detrimental effect on ICP. The hemorrhagic
infarct should not be removed because neuronal damage is often less pronounced in CVT-
related hemorrhage explaining the possible reversibility of even severe clinical symptoms.
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ENDOVASCULAR THROMBOLYTIC THERAPY
Endovascular thrombolytic therapy is reported as a safe and effective treatment for CVT in
some uncontrolled case series,  unless pretreatment cerebral haemorrhages are present. Because
it is invasive and potentially dangerous it should be considered only in patients with a poor
prognosis. Thrombolytic agents deployed were streptokinase,and recombinant tissue
plasminogen activator (rtPA).The benefit to risk ratio of these treatments is still unknown.Local
thrombolysis is believed to better restore venous blood flow than heparin alone.Hemorrhagic
risk is higher in thrombolysis compared to heparin, especially when a pretreatment hemorrhage
is already present.Thrombolysis is also used when the patient’s condition worsens despite
heparin and symptomatic treatment. Clinical deterioration due to thrombosis progression in
properly anticoagulated patients is rarely observed. When it is observed, a thrombolytic
treatment should be considered as a valid option.
PROGNOSTIC FACTORS
 Ferro and colleagues 61 found that age of more than 37 years, male sex, coma, seizure,
mental status disorder, deep CVT, right intracranial hemorrhage, posterior fossa lesion,
worsening of previous focal or de novo focal de?cits, central nervous system infection, and
cancer were predictors of death or dependence.Cancer, coma, and intracranial hemorrhage were
con?rmed as predictors of poor outcome in other studies.
 Isolated intracranial hypertension and a delta sign on CT were associated with a good
outcome. Involvement of the straight sinus also predicted poor outcome.
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PROGNOSIS
Overall prognosis of CVT is fairly good, at least for independent survival of 83%.
Between 57 and 86% of patients have complete functional recovery. Mortality ranks between
5.5% and 18% in recent series. Even though there appears to be no clear correlation between
disease severity and outcome, several factors are associated with a poorer prognosis. These are,
most importantly, infancy and advanced age, rapid onset with coma and focal de?cits, and
thrombosis affecting largely the deep venous system. The underlying condition, particularly
sepsis, malignancy, and paroxysmal nocturnal haemoglobinuria adversely affect outcome.
Twelve per cent of patients had a recurrence of CVT and 14% a different form of venous
thrombosis. Seizures rarely occur beyond the acute stages27.The outcome of CVT is therefore
generally favourable and aggressive and potentially dangerous therapeutic intervention should
be con?ned to those patients who deteriorate rapidly despite heparin or who demonstrate poor
prognostic indicators.
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FUTURE PREGNANCIES
Pregnancy and in particular puerperium are known risk factors for CVST. The risk of
complications during future pregnancies was low. In fact, 88% of the pregnancies ended in a
normal birth, however. except for spontaneous abortions, other complications rarely occurred
during or after new pregnancies.Based on the available evidence, CVT is not a contraindication
for future pregnancies. The same applies for pregnancy/puerperium-related CVT.
Antithrombotic prophylaxis during pregnancy is probably unnecessary, unless a prothrombotic
condition or a previous thromboembolism has been identified.
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                                  Clinical workup of patients with CVT
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MATERIALS AND METHODS
               The study design was prospective observational study involving patients admitted in
Medicine and Neuromedicine wards at Government Stanley Hospital, Chennai. Patients admitted
and diagnosed to have cerebral venous sinus thrombosis based on CT/ MRI & MRV  above the
age of 12 years were included in  study group.
METHODOLOGY
1.Various clinical features of the patients in a predesigned proforma one allotted for each patient.
2.Detailed history about risk factors for CVT was obtained from patients or their relatives.
3.Detailed general examination and neurological examination including, Fundus examination
was also done and were recorded in the individual proforma.
4.CT / MRI & MRV findings were also  recorded.
5.All the patients were done  Fasting Serum Homocysteine and analysed.
6.Patients were asked to come for followup after one month and their functional and neurological
status were recorded and analysed.
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RESULTS AND OBSERVATION
A total of 50 patients of cerebral venous sinus thrombosis were admitted during our study period
and analysed. Of these Males were 27(54%) and Females were 23(46%) ranging from 18  to 68
years.
Table 1.    Total cases of CVT
Male Female Total
27(54%) 23(46%) 50
Majority of the cases affected were in the age range of 21-40 years,constituting a total of
44 of 50 cases( 88%), 2cases(4%) were aged <20 years,3 cases(6%) were between 41-60 years
and 1 case(2%)was found aged >60 years. Median age of occurrence of cerebral venous sinus
thrombosis was 28 years. Among the age group distribution in 21-40 years,22 cases(56%) were
males and 22(44%) females.
                 Table 2.   Age Group Distribution of CVT cases
Age group Male Female Total
?20 yrs 1 1 2(4%)
21-40 yrs 22 22 44(88%)
41-60 yrs 3 - 3(6%)
>60 yrs 1 - 1(2%)
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In our study,among the clinical features the most common symptom was headache. It was
present in 42 of 50 patients (84%). The next common presentation was seizures in 26 cases
(52%). Other symptoms noted were vomiting in 23 cases(46%), focal neurological deficit in 23
cases (46%), Right hemiparesis in 11 (22%) cases, Left hemiparesis occurred in 7
(14%),quaiparesis in 2 (4%) patients, altered sensorium in 16 cases (32%),visual disturbances in
14 cases(28%),neuropsychiatric disturbances in 3 case(6%) and cerebellar disturbances in 2
cases (4%). Right hemisensory loss was present in 3 (6%) cases.
Among  those  who  presented  with  seizures,  focal  seizures  was  observed  in  7
patients(14%), generalized seizures in 15 cases(30%) and status epilepticus occurred in 4
case(8%).  Among 50 patients mode of onset was acute within 2 days in about 13(26%) patients,
subacute  3-28 days onset in 34(68%) patients and chronic >28 days in  about 3(6%) patients.
Table 3. Mode of onset of CVT
Mode of onset No. of patients
Acute                <2 days 13(26%)
Subacute           3-28 days 34(68%)
Chronic           >28 days 3(6%)
Out of the 23 female patients, history of recent delivery present  in 14 cases(61%). One
patient had undergone caesarean section. Among these cases 5 had pregnancy induced
hypertension(10%).
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 History of recent diarrhea was present in one patient about 2 days prior to onset of
symptoms. History of smoking was present in 15 males (55%) and alcohol consumption was
present in 13 patients (48%).Previous deep vein thrombosis occurred in a patient (2%).
On admission Glascow Coma Scale was assessed. GCS was ?8/15 in 2 patients (5%), 9-
13/15  in 20 patients (40%) and more than 13/15 in 28 patients (56%).
Table 4.GCS Distribution of cases
Glascow coma scale ?8/15 9-13/15 >13/15
No. of patients 2(5%) 20(40%) 28(56%)
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Table 5.SIGNS AND SYMPTOMS OF CVT
Symptoms/signs No of
patients
Percent
age
Headache 42 84%
Vomiting 23 46%
Seizures Total 26 52%
Focal seizure 7 14%
Generalized seizure 15 30%
Status epilepticus 4 8%
Motor deficit Total 20 40%
Right hemiparesis 11 22%
Left hemiparesis 7 14%
Quadriparesis 2 4%
Cranial nerve palsy Total 19 38%
Papilloedema 29 58%
Altered sensorium 16 32%
Visual disturbance 14 28%
Neuropsychiatric disturbance 3 6%
Cerebellar disturbance 2 4%
Sensory loss 3 6%
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Cranial nerve palsies occurred in 19(38%) patients. Of the cranial nerves, most
commonly affected were CN VI and CN VII.  VIth   cranial nerve involvement was seen in 11
(22%) patients. VIIth cranial nerve was involved in 9 (18%) patients. IX and X cranial nerves
were affected when Sigmoid sinus was affected. Papilloedema was found in 29(58%) patients.
Motor deficits occurred in 20(40%) patients. Rt.hemiparesis was found in 11 patients (22%).Left
hemiparesis was found in 7 (14%) patients. Quadriparesis was present in two cases (4%).Three
patients had sensory loss(6%). Cerebellar signs were present in 2 (4%) patients. Isolated
intracranial hypertension occurred in 13 (26%) patients.
 Haemoglobin of lessthan 10 gm/dl was present in 14 (28%) of patients.
CT Brain performed in 43 patients suggested abnormalities in 34 (79%) patients but was
normal in 9(21%) patients. Venous infarct  occurred in 6(14%)  patients. Infarct with associated
hemorrhage was observed in 13(30%)  patients. Direct signs of cerebral venous sinus thrombosis
in CT Brain occurred in in 15 (38%)  patients. Intracerebral haemorrghage was present  in 2
patient (5%). Table  6.   CT Features of CVT( n=43)
CT findings No. of cases
Normal 9(21%)
Venous infarct 6(14%)
Infarct with hemorrhage 13(30%)
Intracerebral hemorrhage 2(5%)
Direct signs of CVT 15(38%)
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MRI Brain was done in all 50 cases. Among the sinuses involved Superior Saggital Sinus
was involved in 40 (80%).Next common  sinuses involved were Transverse sinus in
32(64%),Sigmoid Sinus in 20 (40%),Straight sinus in 5 (10%) Internal Jugular Vein in 7
(14%)and Great vein of Galen in 5 (10%).Both Superior Saggital and Transverse sinus were
involved in 28 (56%) of cases.
Table 7.  Sinuses involved in CVST (n=50)
Sinus involved No. of cases
Superior Saggital sinus 40(80%)
Transverse sinus 32(64%)
Sigmoid sinus 20(40%)
Straight sinus 5(10%)
Great vein of Galen 5(10%)
Internal jugular vein 7(14%)
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Serum Homocysteine was done in 50 patients. It was elevated in 11 (22%) patients.  Of
these males were 10  and females constituted one patient.Stastical significance was found for
homocysteine and CVT with a P value of less than o.o5
Table 8. Serum Homocysteine and CVT
TOTAL CASES 50 HYPERHOCYSTEINEMIA
MALE 27 10
FEMALE 23 1
P value <0.05 significant
Table 9.Risk Factors for CVT
Risk factors for CVT Male Female Total
Postpartum state - 14(55%) 14(28%)
H/o chicken pox 1(2%) - 1(2%)
H/o recent diarrhoea 2(4%) - 2(4%)
H/o previous DVT - 1(2%) 1(2%)
CNS infection 1(2%) - 1(2%)
Hyperhomocysteinemia 10(28%) 1 11(22%)
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Outcome at one month was assessed. Mortality was noted in 1 patient(2%),permanent
blindness was noted in 1 patient(2%) and 2 patients(4%) developed permanent motor deficit. 46
patients(92%) showed significant improvement at the end of first month without any residual
deficit.A female patient who had residual deficit developed recurrent deep vein thrombosis at
third week of followup.
Table 10.   Outcome of CVT at 1 month
Group Male Female TOTAL
Good improvement 25 21 46(92%)
Residual deficit 1 1 2(4%)
Blindness 1 - 1(2%)
Death - 1 1(2%)
Recurrent DVT - 1 1(2%)
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DISCUSSION
Cerebral venous sinus thrombosis is a challenging condition because of its variability of
clinical symptoms and signs. A high index of clinical suspicion is needed to diagnose this
uncommon condition so that appropriate treatment can be initiated.
DEMOGRAPHY (Table 1 &2)
A total of 50 patients of cerebral venous thrombosis admitted in our institution were
taken into our study.Among them, 27  were males (54%) and 23 (46%) were females, with an
age range of 18 years to 68 years. Cerebral venous thrombosis is usually a disease of female
preponderance with a male to female ratio of 40:60. But our study had a slight  male
preponderance.  It  may  be  due  to  the  fact  that  female  patients  delivered  in  our  hospital   might
have got admitted with puerperial CVT  in some other hospitals or due to the rising incidence of
CVT among males because of  high prevalence of both smoking and alcoholism. In our study
smoking and alcohol consumption was seen in about 55% and 48% of males respectively.
Whether this could have been a confounding factor  has to confirmed by further large studies.
Bhojo A. Khealani et al76 in his study of 109 cases of CVT reported a female to  male ratio of
57%:43%.  Ameri  and  Bousser  et  al 23 had  found  a  female  to  male  ratio  of  1.29:1  Female
preponderance was mainly due to pregnancy and puerperium and oral contraceptives. In our
study, none of the females gave history of oral contraceptives intake.
In our study median age of the affected patients was 28 years. Pillai LV et al2 has
reported the median age of 32.27 years. DeBruijn et al37 also has reported median age 33 years in
his study of 59 cases  of  CVT. Hence CVT should be considered in  cases of young stroke in
appropriate clinical setting.
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In our study,among the patients affected majority were in the age group of 21-40 years
which constituted a total of 44 cases(88%), 2 cases(4%) were aged <20 years, 3 cases(6%) were
between 41-60 years and 1 case(2%)was aged >60 years. Among the age group of 21-40
years,males were 22(44%) and females were 22(44%). It shows that CVT is the disease of young
adults. Ameri and Bousser et al23 reported a uniform age distribution in men with cerebral venous
thrombosis, while 61% of women with CVT were aged 20-35 years. This may be related to
pregnancy or the use of oral contraceptives.
GLASCOW COMA SCALE (Table 4)
On admission Glascow Coma Scale (GCS) was assessed. It was ?8/15 in 2 patients(4%)
who presented to us after 10 days of  onset of  symptoms. Glascow Coma Scale of more than 9-
13/15 was found in 20 patients (40%). Glascow Coma Scale more than 13 was found in 28
patients(56%). deBruijn et al 37 in his study of 59 cases has found Glascow Coma Scale ?8 in
9(15%) patients  on admission which was considered a poor prognostic indicator. In our study
GCS ?8 was present in 4% patients who had a poor outcome.
CLINICAL FEATURES (Table 5)
In our study,among the clinical features the most common symptom was headache. It was
present in 42 of 50 patients (84%). The next common presentation was seizures in 26 cases
(52%). Other symptoms noted were vomiting in 23 cases(46%), focal neurological deficit in 23
cases (46%),Right hemiparesis in 11 (22%) cases,Left hemiparesis occurred in 7
(14%),quaiparesis in 2 (4%) patients, altered sensorium in 16 cases (32%),visual disturbances in
14 cases(28%),neuropsychiatric disturbances in 3 case(6%) and cerebellar disturbances in 2
cases (4%). Right hemisensory loss was present in 3 (6%) cases.
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Ferro JM et al35 also has reported the presentation of CVST as variable and the incidence
of headache was 92%,motor deficit 42%, seizures 37%, papillodema 45%, sensory deficit of
11%, delirium 25%, cerebellar signs 4% and stupor/coma in 13% of patients.
In our study among the patients with seizures, focal seizures occurred in 7
patients(14%),generalized seizures occurred in 15 patients (30%) and status epilepticus occurred
in 4 patients (8%). Ferro JM et al 43 in a consecutive series of patients with cerebral venous
thrombosis, observed that early symptomatic seizures were found in 44.3% of all patients while
status epilepticus was found to occur in 12.8% of patients . Seizures are more typical in patients
with parenchymal lesions, sagittal sinus and  cortical vein thrombosis, and motor or sensory
defects61. Motor deficit, intracranial hemorrhage, and cortical vein thrombosis are independent
predictors of early epileptic seizures61.
RISK FACTORS (Table 9)
Out of the 23 female patients, 14(61%) had recent delivery . One patient had undergone
caesarean section.. Among these cases 5 had pregnancy induced hypertension (36%) during their
antenatal period..
Srinivasan et al20  in a clinical study of 135 patients reported Cerebral venous thrombosis
occurring in puerperium is about 10 to 12 times more frequent in India than in Western
countries. In western studies a frequency of  only 5-20%  of CVT was present in puerperial
period. In a study from Mexico by Cantu et al, about 60% of CVT occurred during pregnancy
and puerperium22. Many risk factors have been implicated in the pathogenesis of peripartum and
puerperium CVST. These include dehydration, anemia22, cesarean delivery, hypertension,
infections , the mother’s age (more common in women aged 15–24 years than in those aged 25–
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34 years) 77, and thrombophilia78. Pregnancy/puerperium-related CVT may more commonly have
a sudden or acute onset and a progressive course that tends to become stable in a few days and a
better prognosis than nonobstetric CVT22 .
Among the risk factors recent diarrhea was present in 2 patients (4%). Past history of
deep vein thrombosis was present in one patient,  one patient had recent chickenpox infection
and one patient had CNS infection in the form of temporal lobe abscess.
FOCAL NEUROLOGICAL DEFICIT (Table 5)
In our study cranial nerve palsies occurred in 19 (38%) patients. Of the cranial nerves
most  commonly  affected  were  CN  VI  and  CN  VII.  VIth cranial nerve was the most common
cranial nerve to be involved in 11(22%) patients. VIIth cranial nerve was involved in 9(18%)
patients. Kuehnen J et al   reports cranial nerve palsies in 12% of all cases of cerebral venous
thrombosis. The cranial nerves that have been described to be involved are III, IV,V, VI, VII,
VIII, IX, X and XI, and the involvement can be multiple or single. cases,
Papilloedema was found in 29 (58%) patients. Ferro JM et 35 al has also reported
papillodema in 45% of patients with CVT. Bhojo A. Khealani et al 76 has found in a series of 59
patients, papillodema in a frequency of 35%.
 In our study motor deficits occurred in 20(40%) patients. Right hemiparesis was found in
11 patients(22%). Left hemiparesis was found in 7(14%) patients. Quadriparesis was present in
two cases (4%). Bhojo A. Khealani et al 76  has reported a frequency of 45% of patients with motor
deficits  in a series of 59 cases which correlates with our study. Three patients had sensory loss (6%).
Cerebellar signs were present in 2(4%) patients.
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Isolated intracranial hypertension
Isolated intracranial hypertension occurred in 13(26%) patients.Ferro JM et al 35has found
about isolated intracranial hypertension was the only  presentation  in about 29% of patients with
CVT.  deBrujin et al 37 also has reported about 20% of patients presenting with only isolated
intracranial hypertension in the absence of any focal neurological deficit and normal CT Brain
for whom the prognosis is generally good.
Haemoglobin  of  lessthan  10  gm/dl  was  present  in  14  (28%)  of  patients.  Anaemia  was
associated with increased risk of CVT as the study by Stolz et al 30.
CT IMAGING (Table 7)
CT Brain done suggested abnormalities in 34 (80%) of  patients. It was normal in 9(21%)
patients. Provenzale JM et al 65 has reported that CT Brain can be misinterpretated as normal in
upto 40% of patients. Cantu et al 22 has described normal CT Brain in about 9.47% of patients in
his study. Contrast administration is almost always required to increase the reliability of CT in
diagnosing CVT. In our study venous infarct occurred in 6(14%) patients, infarct with associated
haemorrghe in 13(30%) patients. Direct signs of cerebral venous sinus thrombosis in CT Brain
occurred in 15(38%) patients. Intracerebral haemorrhage was present  in two patients
(5%).Thalamic infarct occurred in 2 (5%) patients.
MRI IMAGING (Table 8)
In our study MRI Brain with venogram was done in all 50 patients. Among the sinuses
involved Superior Saggital Sinus was involved in 40(80%) casaes .Next common  sinuses
involved were Transverse sinus in 32(64%) cases, Sigmoid Sinus in 20(40%) cases, Straight
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sinus in 5(10%) cases, Internal Jugular Vein in 7(14%) cases and Great vein of Galen in 5(10%)
cases. Both Superior Saggital and Transverse sinus were involved in 28(56%) of cases. Bhojo A.
Khealani et al 76  has reported Superior sagittal sinus involvement in 77(71%) cases, Transverse
sinus involvement in 51(47%) cases, Sigmoid sinus involvement in 34(31%) cases, Straight sinus
involvement in 11(10%) cases, Deep cerebral veins involvement in 8(3%) cases, Cortical veins
in 7 (6%) cases and Internal jugular vein in 4(4%) cases in a series of 109 patients.
SERUM HOMOCYSTEINE (Table 9)
In our study  fasting serum Homocysteine was done in all fifty patients. It was elevated in
11(22%) patients. Bhojo A. Khealani et al 76  has reported hyperhomocysteinemia  in about 29%
of patients tested for serum homocysteine. Ida Martinelli et al 79 has reported a incidence of
hyperhomocysteinemia in 27% of patients in a study of 121 patients. Hyperhomocysteinemia is
associated with a 4-fold increased risk of cerebral vein thrombosis79.
OUTCOME AT 1 MONTH (Table 10)
In our study,all  patients received immediate anticoagulation with IV Heparin after
confirmation by MRI Venography followed by oral Warfarin to maintain target INR of 2-3,
along with antiedema measures. Outcome at one month was assessed. Mortality was seen in one
patient(2%). In ISCVT study  by Ferro GM et al 72 the majority of deaths after CVT occur during
the  first  days with a mortality rate of 4.3% due to transtentorial herniation. In an Indian study
Nagaraja et al 80 has reported a mortality of 17%. Treatment with anticoagulant drugs leads to a
moderate bene?t for patients with CVT compared with placebo treatment,but the mortality after
treatment with anticoagulant drugs is still 5% to 10%.72
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 In our study 2(5%) cases developed residual  motor deficits. Biousse et al81 has reported
in series of 160 patients about 5% had developed permanent motor deficit and became
dependent. This correlates with our study.
In our study one patient developed permanent blindness(2%) due to optic atrophy. In the
follow-up of  ISCVT study 72, 4(1%) cases had severe visual loss. This complication was also
rare in the study by Preter et al. 82 where 2 patients (2.6%) were left with blindness due to optic
atrophy. In the Lille study, 2(3.6%) patients had a decreased visual acuity due to optic nerve
atrophy 83. Biousse et al.81 systematically examined 59 out of 160 CVT consecutive patients with
the isolated intracranial hypertension syndrome. 3(5%) cases developed optic atrophy with
severe visual loss. In our study all the other patients (90%) had improved significantly well.
In our study one (2%) patient who had residual neurological deficit developed thrombosis
of deep venous system of leg. In the ISCVT 72, 4.5% of patients had recurrent thrombosis, more
frequently in the peripheral venous system. Gosk-Bierska et al. 84 series estimated an event rate
of recurrence  of thrombosis at a rate of  2.8/100 patient-years.
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CONCLUSION
1. A total of 50 cases of CVT were studied.CVT is a disease of young adults.About 44 (88%) of
patients were in the age group of 21-40 years.CVT  has to be considered in differential
diagnosis of young stroke as it affects often people in the age group of 21-40 years.56% of them
were males and 44% were females.
2. Mean age of affected patients was 28 years.
3. CVT is more common in females in postpartum period when they have associated anaemia,
and hypertension.
3. CVT has to be suspected in any patient with symptoms such as headache, seizures and focal
neurological deficit as they are the most common clinical feature.
4. CVT can also present only with isolated intracranial hypertension
5. CT Brain is normal in upto 9(21%) of patients. Normal CT Brain doesnot  ruleout CVT. So to
confirm the diagnosis of CVT, MRI has to be done in all suspected cases.
6. Among the sinuses Superior Saggital Sinus is most commonly involved in 80% of patients
followed by Transverse Sinus in 64% and Sigmoid sinus in 40% of cases.
7. Risk factors for CVT found are recent diarrhea in two(4%) patients, recent chicken pox in
one (2%) patient, previous DVT one 2(%) patient, hyperhomocysteinemia in about 11(22%) of
patients and  CNS infection in one (2%) patient.
8. Initiation of heparin therapy followed by oral anticoagulants favours early recovery of
neurological deficit and prevents further complications.
9. Followup at one month one patient has died with a mortality rate of 2%.One had permanent
blindness and two patients had residual deficit.
10. CVT generally has a favourable prognosis.
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ABBREVIATIONS
CVT                         Cerebral Venous Thrombosis
SSS                           Superior Sagittal Sinus
TS                             Transverse  Sinus
SS                             Straight  Sinus
GTCS                       Generalised Tonic clonic Seizures
CT                            Computed Tomography
MRI                          Magnetic Resonance Imaging
MRV                        Magnetic Resonance venography
LMWH                     Low molecular weight heparin
ICP                           Intracranial pressure
ANA                         Anti Nuclear Anti body
APLA                       Anti Phospholipid Antibody
PROFORMA
S.No:                                                            D.O.A:                         D. of Delivery:
Name                                Age/ Sex             D.O.D:
Para:                       Gravida:                          Interval between delivery & first symptom:
SYMPTOMS:                                                Interval between first symptom & admission:
Headache:                                 Duration:
Vomiting      :
Visual disturbances:
Seizures:               Focal:             Generalized:                   Status:
Consciousness:     Normal / Altered: (Duration):
Focal deficits:       Motor: Hemiparesis / monoparesis / paraparesis / quadriplegia
                              Sensory:
Altered behavior:
Fever:
Recent delivery:                Place                    Normal / LSCS      PIH during pregnancy
PAST HISTORY :
CVST:                DM:               HT:                  Hematological disorder   Smoking:
Ear discharge:                       OCP:               Renal disease:                 Alcohol intake:
Exanthematous fever:                       Cancer:                                      Recent surgery:
Bloody diarrhea:                               Vasculitis (rash, arthritis):
EXAMINATION:
Pulse:            BP:                    Temp:
Consciousness:                       Orientation:                                       Behaviour:
Language:
Meningeal signs:
Pupils:                                    Fundus:
Motor system                        Weakness                              Power                             Tone
Reflexes
Sensory system
Cerebellar signs
Bladder involvement
CVS                                    RS                                           ABDOMEN
INVESTIGATONS:
Hb                               ESR:                    TC:                                  Urine:
S. Homocysteine:
Blood sugar                              Urea                            S.Creatinine:
Electrolytes                              CXR
ECG
CT scan:        plain / contrast                  Normal / Abnormal
 Direct signs – empty delta sign / dense triangle sign / cord sign (SSS / LS /Medullar
 Indirect signs – hemorrhagic infarct / non hemorrhagic infarct /
                                   Location -
MRI & MRV:
             Hemorrhagic infarct / non hemorrhagic infarct /
             Location -
             Sinus involved –
OUTCOME :
PRESENTATION   :      acute / subacute / chronic
SINUS INVOLVED:   SSS / LS/ TS/ SS / Cortical vein / Deep venous system
DIAGNOSIS:
OUTCOME AT 1 MONTH FOLLOWUP:
KEY TO MASTER CHART
Sex M-Male,F-Female
HA-Headache 0-Absent,1-Present
Vo-Vomiting 0-Absent,1-Present
Sz-Seizures 0-Absent,1-Present
VD-Visual disturbances   0-Absent,1-Present
MD-Motor deficit             R-Right,L-Left,UL-Upperlimb,LL-Lowerlimb
SD-Sensory loss R-Right
Speech disturbance 0-Absent, 1-Present
Alt.S-Altered sensorium     0-Absent, 1-Present
Acute onset 0-Absent, 1-Present
Subacute onset 0-Absent, 1-Present
Chronic onset 0-Absent, 1-Present
Recent delivery 0-Absent, 1-Present
PIH 0-Absent, 1-Present
Risk factors 0-Absent,1-Diarrhoea,2-DVT,3-Temporal abscess,4-Chicken pox
SMO-Smoking                    0-Absent, 1-Present
ALC-Alcohol                       0-Absent, 1-Present
Cranial nerves 0-Normal,1-Cranial nerve palsy
Motor system 0-Normal,1-Rt.hemiparesis,2-Lt.hemiparesis,3-Quadriparesis
Sensory system 0-Normal,1-Rt.sensory loss
Cerebellum 0-Normal,1-Cerebellar signs
Fundus 0-Normal,1-Papillodema
CT Brain 0-Not done
Serum Homocysteine Normal-5.50-16.20µmol/l
Outcome 1-Improved,2-Residual deficit,3-Death,4-Blind,5-Recurrent DVT
MASTER CHART- CLINICAL FEATURES OF  CVT
S.N
o
Ag
e
Se
x HA Vo SZ VD MD SD speech Alt. S Cere. S BD Acute SubAc Chr
Rec.
del PIH
Risk
fact
ors SMO ALC
1 23 M 1 1 0 1 1 0 1 0 0 0 1 0 0 0 0 1 0 0
2 42 M 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1
3 38 F 1 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0
4 23 F 1 1 1 0 1 0 0 1 0 0 1 0 0 1 0 0 0 0
5 38 F 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 2 0 0
6 29 F 1 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0
7 30 M 1 0 0 0 1 0 1 0 1 0 1 0 0 0 0 3 1 0
8 18 M 1 1 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
9 28 M 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
10 29 M 1 0 1 0 1 1 0 0 0 0 0 1 0 0 0 0 1 0
11 51 M 1 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 1
12 35 M 1 0 1 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0
13 25 F 1 0 1 0 2 0 0 0 0 0 1 0 0 1 1 0 0 0
14 27 M 1 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0
15 28 F 1 0 1 0 2 0 0 1 0 0 0 1 0 1 0 0 0 0
16 21 F 1 0 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0
17 20 F 1 1 1 0 3 0 0 1 0 0 1 0 0 1 0 0 0 0
18 30 M 1 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 1 1
19 34 M 1 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0
20 23 M 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1
21 23 M 1 1 0 1 2 0 0 0 0 0 0 1 0 0 0 0 1 1
22 68 M 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0
23 40 M 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0
24 39 M 1 0 0 1 0 0 0 0 0 0 0 1 0 0 0 4 0 0
25 27 F 0 0 1 0 0 0 0 0 0 1 1 0 0 1 1 0 0 0
MASTER CHART- CLINICAL FEATURES OF  CVT
S.No Age Sex HA Vo SZ VD MD SD speech Alt. S Cere. S BD Acute SubAc Chr
Rec.
del PIH
Risk
fact
ors SMO ALC
26 24 F 1 0 1 0 0 0 0 0 1 0 1 0 1 1 0 0 0
27 44 M 1 1 0 0 2 0 0 0 0 0 0 1 0 0 0 0 1 1
28 23 M 1 1 0 1 3 0 0 0 0 0 0 1 0 0 0 0 0 0
29 25 F 1 0 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0
30 27 F 0 0 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0
31 29 F 1 1 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0
32 35 F 1 0 0 1 0 0 0 0 0 0 0 0 1 1 1 0 0 0
33 27 M 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1
34 35 M 1 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 1 1
35 37 M 1 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 1 1
36 25 F 1 0 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0
37 30 F 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
38 27 F 1 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0
39 35 M 1 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1
40 31 F 1 1 0 1 1 0 0 1 0 0 0 1 0 0 0 0 0 0
41 28 M 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
42 23 M 1 1 0 1 1 0 1 0 0 0 1 0 0 0 0 1 0 0
43 42 M 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1
44 38 F 1 1 1 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0
45 23 F 1 1 1 0 1 0 0 1 0 0 1 0 0 1 0 0 0 0
46 35 M 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 1
47 26 M 1 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1
48 25 F 1 1 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0
49 27 F 0 0 1 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0
50 27 F 0 0 1 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0
S.No MRI MRV showing thrombosis S. Homo. Outcome
1
Right.Putamen
infarct
SSS,St.sinus,L.Transverse
sinus,L.Sigmoid
sinus,Galen,Sup.cortical vein 24.13 1
2 NORMAL SSS&Rt.Tranverse sinus 10.23 1
3 NORMAL
SSS,Rt.Transverse
sinus&Rt.Sigmoid sinus 12.43 1
4
Lt.parietal infarct
with haemorrhge SSS 11.29 1
5
Bilateral Thalamic
infarct
Rt.Straight sinsus,Rt.Transverse
sinus,Vein of Galen 8.9 2,5
6
Rt.parietal
haemorrhge
SSS,Rt.Transverse&Rt.Sigmoid
sinus&Rt.IJV 12 1
7 BL. Cerebellar infarct Lt.Sigmoid,St.sinus&IJV thrombosis 9.7 1
8 NORMAL
SSS,Rt.Transverse
sinus,&Rt.Sigmoid sinus 5.89 1
9
Venous infarct in
Lt.parietal lobe SSS 11.5 1
10
Lt.Frontoparietal
infarct
withhaemorrhge
SSS,St.sinus,Rt.Lateral ,Rt.jugular
bulb&SigmoidSinus 31.69 1
11 NORMAL SSS,Bl Transverse,&Sigmoid sinus 30.1 1
12
Venous infarct in
Rt.Frontalparietal
lobe Sup.cortical vein&St.sinus 28.33 2
13
Venous infarct in
Rt.Frontal and
parietal lobe
SSS,St.sinus,Lt.Transverse
sinus&Inf.cerebral vein 23.56 1
14
Rt.Frontal infarct
with haemorrhge SSS 11.42 1
15
Bl.Parietal
&Lt.Frontal venous
infarct SSS&Rt.Tranverse sinus 12.43 1
16
BL Parietal infarct
with cerebral
oedema SSS&Rt.Transverse sinus 7.8 3
17 NORMAL SSS 9.2 1
18 Bl.Thalamic infarct
SSS,Rt.Tranverse sinus,Rt.Sigmoid
sinus,Rt.IJV&Great vein of Galen 9.5 1
19
Infarct
Rt.postr.parietal
cortex SSS 7.8 1
20 NORMAL
SSS,Bilateral Tranverse
sinus&Sigmoid sinus 21.12 4
21
Lt.parietal
haemorrhge SSS,St.sinus,Lt.Tranverse sinus 8.9 1
22 NORMAL Lt.Sigmoid sinus thrombosis 13.2 1
23 NORMAL
SSS,Rt.Tranverse sinus,Rt.Sig
sinus,Rt.Internal jugular vein 42.43 1
24 Rt.Frontal&Parietal SSS,Rt.Tranverse sinus,&Rt.Sig 11.8 1
infarct haemorrhge sinus
25
Venous infarct in
Lt.parietal lobe SSS 6.9 1
26
Venous infarct in
Lt.parietal lobe SSS&Rt.Tranverse sinus 12.9 1
27
Rt.parieto ccipital
infarct with odema
Rt.Transverse,&Rt.Sigmoid sinus
&Rt.Internal jugular vein 28.9 1
28 NORMAL SSS,Bl Transverse,&Sigmoid sinus 30.2 1
29 NORMAL SSS 6.9 1
30 NORMAL SSS 7.41 1
31 NORMAL Lt.transverse &Sigmoid sinus 9.67 1
32 NORMAL SSS&Rt.Transverse sinus 13.67 1
33 NORMAL SSS&Rt.Transverse sinus 25.6 1
34
Bl.Frontoparietal
haemorrghic infarct SSS 18.5 1
35
Rt.parieto occipital
infarct with
haemorrhge
SSS,Rt.Tranverse sinus,&Rt.Sig
sinus 10.2 1
36 NORMAL SSS 12.1 1
37 NORMAL Rt.Tranverse sinus,&Rt.Sig sinus 11.2 1
38
Lt.parietal venous
infarct SSS&Rt.Transverse sinus 12.4 1
39 Lt.parietal infarct Lt.Sigmoid thrombosis 9.56 1
40
Lt.parietal infarct
with haemorrhge Lt.Sigmoid&IJV thrombosis 10.78 1
41 NORMAL SSS,Bl Transverse,&Sigmoid sinus 10.6 1
42
Right.Putamen
infarct
SSS,St.sinus,L.Transverse
sinus,L.Sigmoid
sinus,Galen,Sup.cortical vein 19.13 1
43 NORMAL SSS&Rt.Tranverse sinus 10.23 1
44 NORMAL
SSS,Rt.Transverse
sinus&Rt.Sigmoid sinus 12.43 1
45
Lt.parietal infarct
with haemorrhge SSS 11.59 1
46
Lt.parietal
haemorrhgic infarct
Rt.Straight sinsus,Rt.Transverse
sinus,Vein of Galen 12.43 1
47
Rt.parietal
haemorrhge
SSS,Rt.Transverse&Rt.Sigmoid
sinus&Rt.IJV 12.4 1
48 NORMAL SSS &Transverse sinus 7.34 1
49 NORMAL SSS 9.78 1
50
Lt.parietal
haemorrhgic infarct SSS 11.32 1
